EP1835928A2 - Mas g protein gekoppelte rezeptoren als arzneitargets - Google Patents
Mas g protein gekoppelte rezeptoren als arzneitargetsInfo
- Publication number
- EP1835928A2 EP1835928A2 EP05821505A EP05821505A EP1835928A2 EP 1835928 A2 EP1835928 A2 EP 1835928A2 EP 05821505 A EP05821505 A EP 05821505A EP 05821505 A EP05821505 A EP 05821505A EP 1835928 A2 EP1835928 A2 EP 1835928A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- mrge
- seq
- polypeptide
- fragment
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title abstract description 53
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title abstract description 53
- 239000003596 drug target Substances 0.000 title description 5
- 230000000694 effects Effects 0.000 claims abstract description 28
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 26
- 208000008589 Obesity Diseases 0.000 claims abstract description 23
- 235000020824 obesity Nutrition 0.000 claims abstract description 23
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 11
- 101150041973 Mrgpre gene Proteins 0.000 claims description 248
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 126
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 118
- 229920001184 polypeptide Polymers 0.000 claims description 117
- 239000012634 fragment Substances 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 61
- 150000001875 compounds Chemical class 0.000 claims description 45
- 210000004027 cell Anatomy 0.000 claims description 41
- 230000014509 gene expression Effects 0.000 claims description 40
- 230000027455 binding Effects 0.000 claims description 34
- 239000002773 nucleotide Substances 0.000 claims description 28
- 125000003729 nucleotide group Chemical group 0.000 claims description 28
- 102000040430 polynucleotide Human genes 0.000 claims description 26
- 108091033319 polynucleotide Proteins 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 26
- 238000012360 testing method Methods 0.000 claims description 26
- 239000003446 ligand Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- 230000000692 anti-sense effect Effects 0.000 claims description 21
- 108020004459 Small interfering RNA Proteins 0.000 claims description 18
- 238000012216 screening Methods 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- 230000003993 interaction Effects 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- -1 or variant thereof Substances 0.000 claims description 3
- 210000004671 cell-free system Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 102000005962 receptors Human genes 0.000 abstract description 29
- 108020003175 receptors Proteins 0.000 abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 102000040470 Mas-related G protein-coupled receptor family Human genes 0.000 abstract description 4
- 108091072415 Mas-related G protein-coupled receptor family Proteins 0.000 abstract description 4
- 150000001413 amino acids Chemical class 0.000 description 53
- 108090000623 proteins and genes Proteins 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 20
- 239000002299 complementary DNA Substances 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 15
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 15
- 239000013615 primer Substances 0.000 description 14
- 108091006027 G proteins Proteins 0.000 description 13
- 102000030782 GTP binding Human genes 0.000 description 13
- 108091000058 GTP-Binding Proteins 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 230000004069 differentiation Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 210000001789 adipocyte Anatomy 0.000 description 11
- 210000000593 adipose tissue white Anatomy 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 210000000229 preadipocyte Anatomy 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 102000030621 adenylate cyclase Human genes 0.000 description 6
- 108060000200 adenylate cyclase Proteins 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 102000000536 PPAR gamma Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000007877 drug screening Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 102100037117 Mas-related G-protein coupled receptor member E Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 108020001756 ligand binding domains Proteins 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108060003345 Adrenergic Receptor Proteins 0.000 description 3
- 102000017910 Adrenergic receptor Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- 108091008767 PPARγ2 Proteins 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000004400 serine Nutrition 0.000 description 3
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- 108010000239 Aequorin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 101150013191 E gene Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101100290181 Homo sapiens MAS1 gene Proteins 0.000 description 2
- 101100131277 Homo sapiens MRGPRX3 gene Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 102100028178 Mas-related G-protein coupled receptor member X3 Human genes 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 108091007261 P2U receptors Proteins 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000001744 Purinergic P2Y2 Receptors Human genes 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 101100402536 Rattus norvegicus Mrgpra gene Proteins 0.000 description 2
- 101100238505 Rattus norvegicus Mrgpre gene Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108010083298 arginylphenylalaninamide Proteins 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 108700010039 chimeric receptor Proteins 0.000 description 2
- 235000014651 chocolate spreads Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000007403 mPCR Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000001044 sensory neuron Anatomy 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- KYRUKRFVOACELK-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(4-hydroxyphenyl)propanoate Chemical compound C1=CC(O)=CC=C1CCC(=O)ON1C(=O)CCC1=O KYRUKRFVOACELK-UHFFFAOYSA-N 0.000 description 1
- CQZWLVDDIOZTJI-RYUDHWBXSA-N (2s)-2-amino-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]-5-(diaminomethylideneamino)pentanamide Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 CQZWLVDDIOZTJI-RYUDHWBXSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XMXLVNVGGJBUPF-UHFFFAOYSA-N 2-amino-n,n-diethyl-1,3-benzothiazole-6-carboxamide Chemical compound CCN(CC)C(=O)C1=CC=C2N=C(N)SC2=C1 XMXLVNVGGJBUPF-UHFFFAOYSA-N 0.000 description 1
- 102100034482 AP-1 complex subunit beta-1 Human genes 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 240000001082 Bambusa multiplex Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102100030851 Cortistatin Human genes 0.000 description 1
- 229930185483 Cortistatin Natural products 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000779222 Homo sapiens AP-1 complex subunit beta-1 Proteins 0.000 description 1
- 101100238514 Homo sapiens MRGPRX1 gene Proteins 0.000 description 1
- 101000891654 Homo sapiens TATA-box-binding protein Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102100037130 Mas-related G-protein coupled receptor member X1 Human genes 0.000 description 1
- 108010024777 Mating Factor Receptors Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101150098845 Mrgprd gene Proteins 0.000 description 1
- 101150033080 Mrgprg gene Proteins 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 101100290182 Mus musculus Mas1 gene Proteins 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical group CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 101800001049 Neuropeptide AF Proteins 0.000 description 1
- 102400001090 Neuropeptide AF Human genes 0.000 description 1
- 101800000150 Neuropeptide AF-like Proteins 0.000 description 1
- 102400001095 Neuropeptide FF Human genes 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000010175 Opsin Human genes 0.000 description 1
- 108050001704 Opsin Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 102100028045 P2Y purinoceptor 2 Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000015925 Proto-oncogene Mas Human genes 0.000 description 1
- 108050004181 Proto-oncogene Mas Proteins 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101100290183 Rattus norvegicus Mas1 gene Proteins 0.000 description 1
- 101100238516 Rattus norvegicus Mrgprx1 gene Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000033040 Somatoform disorder pregnancy Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000003919 adipocyte function Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000036782 biological activation Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 229940098124 cesium chloride Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007585 cortical function Effects 0.000 description 1
- 108010005430 cortistatin Proteins 0.000 description 1
- DDRPLNQJNRBRNY-WYYADCIBSA-N cortistatin-14 Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)NC(=O)[C@H]1NCCC1)C(=O)N[C@@H](CCCCN)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 DDRPLNQJNRBRNY-WYYADCIBSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000000569 greater omentum Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 102000045334 human TBP Human genes 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- DYSIROANKWMSGC-KWFINLGMSA-N npaf Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](C)N)CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=CC=C1 DYSIROANKWMSGC-KWFINLGMSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 230000008050 pain signaling Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 108010055752 phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide Proteins 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010041071 proenkephalin Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Definitions
- the present invention relates to G protein coupled receptors of the MAS related G protein coupled receptor family.
- the present invention relates to modulation of the activity of these receptors.
- MrgE is a seven transmembrane G protein coupled receptor (GPCR) of the MAS related G-protein coupled receptor family (Anderson et al. 2001 ; Dong et al. 2001 ; GoIz et al. 2004; Wei et al. 2002). Many medically significant biological processes are mediated by signal transduction pathways that involve G-proteins (Lefkowitz 1991).
- GPCRs G-protein coupled receptors
- the family of G-protein coupled receptors (GPCRs) includes receptors for hormones, neurotransmitters, growth factors, and viruses.
- GPCRs include receptors for such diverse agents as dopamine, calcitonin, adrenergic hormones, endotheline, cAMP, adenosine, acetylcholine, serotonin, histamine, thrombin, quinine, follicle stimulating hormone, opsins, endothelial differentiation gene- 1 , rhodopsins, odorants, cytomegalovirus, G-proteins themselves, effector proteins such as phospholipase C, adenyl cyclase, and phosphodiesterase, and actuator proteins such as protein kinase A and protein kinase C.
- GPCRs possess seven conserved membrane-spanning domains connecting at least eight divergent hydrophilic loops. GPCRs, also known as seven transmembrane, 7TM, receptors, have been characterized as including these seven conserved hydrophobic stretches of about 20 to 30 amino acids, connecting at least eight divergent hydrophilic loops. Most GPCRs have single conserved cysteine residues in each of the first two extracellular loops, which form disulfide bonds that are believed to stabilize functional protein structure. The seven transmembrane regions are designated as TM1 , TM2, TM3, TM4, TM5, TM6, and TM7. TM3 is being implicated with signal transduction. Phosphorylation and lipidation (palmitylation or famesylation) of cysteine residues can influence signal transduction of some GPCRs.
- GPCRs contain potential phosphorylation sites within the third cytoplasmic loop and/or the carboxy terminus.
- GPCRs such as the beta-adrenergic receptor, phosphorylation by protein kinase A and/or specific receptor kinases mediates receptor desensitization.
- the ligand binding sites of GPCRs are believed to comprise hydrophilic sockets formed by several GPCR transmembrane domains.
- the hydrophilic sockets are surrounded by hydrophobic residues of the GPCRs.
- the hydrophilic side of each GPCR transmembrane helix is postulated to face inward and form a polar ligand binding site.
- TM3 is being implicated with several GPCRs as having a ligand binding site, such as the TM3 aspartat residue.
- TM5 serines, a TM6 asparagine, and TM6 or TM7 phenylalanines or tyrosines also are implicated in ligand binding.
- GPCRs are coupled inside the cell by heterotrimeric G-proteins to various intracellular enzymes, ion channels, and transporters. Different G-protein alpha- subunits preferentially stimulate particular effectors to modulate various biological functions in a cell. Phosphorylation of cytoplasmic residues of GPCRs is an important mechanism for the regulation of some GPCRs.
- the effect of hormone binding is the activation of the enzyme, adenylate cyclase, inside the cell. Enzyme activation by hormones is dependent on the presence of the nucleotide GTP. GTP also influences hormone binding.
- a G-protein connects the hormone receptor to adenylate cyclase.
- G-protein exchanges GTP for bound GDP when activated by a hormone receptor.
- the GTP-carrying form then binds to activated adenylate cyclase.
- the G- protein serves a dual role, as an intermediate that relays the signal from receptor to effector, and as a clock that controls the duration of the signal.
- Mrg GCPR receptor members of the MAS related G-protein coupled receptor family
- Members of this family include MrgA, B, C, D, E, and X.
- MrgA MrgA family
- the MrgD family also seems to be almost exclusively expressed in dorsal root ganglia (Dong et al. 2001). It has been suggested that the MrgA1 and A4 receptors bind neuropeptides, perhaps of the RFamide family (Dong et al. 2001 ).
- MrgA1 and A4, MAS1 , and MrgC11 can be activated by the RFamide neuropeptides NPFF and NPAF, respectively, which have long-lasting analgesic effects when injected intraspinally as well as the specificity of expression of the Mrg families ((Dong et al. 2001 ; Han et al. 2002) has led to suggestions that ligands for most of these receptors include neuropeptides that modulate pain sensitivity.
- the MrgX2 receptor which has no identified rat or mouse homologues has been shown to bind cortistatin (Robas et al. 2003), a peptide previously shown to be involved in sleep regulation, locomotor activity, and cortical function, but which may also play a role in nociception.
- Mrg gene family members of the Mrg gene family, named sensory neuron-specific GPCRs (SNSR) have also been cloned by Lembo and coauthors (Lembo et al. 2002) who found the same tissue specificity of expression and, in addition, found that the non-opioid part of the proenkephalin A gene product BAM22 was a high-affinity ligand for these receptors, substantiating a role of the Mrg/SNS receptors in pain modulation.
- SNSR sensory neuron-specific GPCRs
- WO 0148015 discloses transcripts from G protein-coupled receptors
- MrgX2 transcripts are expressed in human liver and adipose tissue and it is suggested that this protein is linked to metabolic disorders, inflammatory diseases and cancers. MrgX2 exhibits only sparse similarity ( ⁇ 35%) with MrgE. This document furthermore discloses MrgE transcripts (transcript 1002). This transcript is expressed in the brain, heart, kidney, liver, muscle, ovary, prostate, small intenstive, spleen, testis, peripheral blood leukocytes and lung. These observations confirm previous assumptions about the linkage of MrgE with mental disorders.
- MrgE The nucleotide sequence of MrgE is accessible in public databases by the accession number NM_001002288 and is given in SEQ ID NO 1.
- the predicted amino acid sequence of MrgE is depicted in SEQ ID NO 2.
- Human MrgE (accession number XM-171536) is given in SEQ ID NO 3 (nucleotide sequence) and SEQ ID NO 4 (amino acid sequence), respectively.
- MrgE is expressed in humans and in mice (Dong et al. 2001 ; Vassilatis et al. 2003).
- the MrgE receptor (Anderson et al. 2001 ; Dong et al. 2001 ; Lind et al. 2001 ; Miwa et al. 2002; Vassilatis et al.
- MrgE is expressed in the brain (in particular in the hypothalamic sub areas denoted "PVN” and "DMH"), placenta and thyroid (Wang et al. 2001 ) as well as in blood cells and testis (Wei et al. 2002). It has furthermore been suggested that MrgE is implicated in pain signalling (Anderson et al. 2001 ) and in development of mental disorders (Lind et al. 2001 ; Vogeli et al. 2001 a; Vogeli et al. 2001 b).
- MrgE molecules are rather distantly related to other Mrg molecules. Mrg molecules most closely related to MrgE are as follows: sequence identity of about 40.7% between human MrgE and MrgX3 (also denoted SNSR1 ); sequence identity of about 40.2% between human MrgE and MrgX2; sequence identity of about 38.4% between human MrgE and MrgX1 ; sequence identity of about 37.6% between human MrgE and MrgX4; sequence identity of about 36.8% between human MrgE and SNSR2; sequence identity of about 38.4% between human MrgE and SNSR3; and sequence identity of about 37.1% between human MrgE and MrgG.
- Diabetes is characterized by a decreased ability to regulate blood glucose concentrations. Diabetes can be grouped in two major classes: diabetes type I, wherein the insulin-producing cells are partly or fully destroyed by an autoimmune reaction and diabetes type II. wherein the insulin-producing cells are intact or essentially intact and wherein the decreased ability to regulate blood glucose is thought to be caused by decreased insulin-sensitivity. Diabetes type Il is often accompanying obesity. In the present invention, the term diabetes is thus equivalent to diabetes type II. A number of pathological conditions furthermore accompany obesity and/or diabetes such as hypertension, and cardiovascular diseases.
- the present invention lies in the unexpected findings that:
- MrgE transcripts are relatively abundant in preadipocytes. • MrgE expression is down-regulated during differentiation of preadipocytes to adipocytes.
- MrgE is expressed in fat tissue.
- MrgE expression is up-regulated as a response to starving and down- regulated as a response to over-feeding/obesity.
- the present invention thus relates to a composition for use as a medicament, said composition comprising at least one compound selected from the group consisting of:
- a polynucleotide encoding an MrgE polypeptide said polynucleotide comprising the sequence of SEQ ID NO 1 , or SEQ ID NO 3, a fragment, or variant thereof.
- a polynucleotide encoding an MrgE polypeptide wherein said polypeptide comprises the amino acid sequence according to SEQ ID NO 2, or SEQ ID NO 4, or a fragment, or variant thereof,
- an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof
- an MrgE specific antibody raised against an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof
- nucleotide sequence that is antisense to a transcript encoding an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof
- siRNA molecule that is specific to a transcript encoding an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof.
- the present invention relates to use of one of the compounds according to the invention for manufacturing a pharmaceutical for modulating expression of MrgE in fat tissue for treating, alleviating, or preventing obesity, and/or diabetes, and/or cardiovascular diseases.
- the present invention relates to a method of screening an MrgE polypeptide for an interaction partner said method comprising the following steps:
- the present invention relates to a method of screening for therapeutic agents useful in the treatment of obesity and/or diabetes and/or cardiovascular diseases, said method comprising the following steps: (i) determining the activity of an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment or variant thereof, in the presence and optionally also in the absence of a test compound,
- the present invention relates to a method of treating obesity and/or diabetes, wherein at least one compound selected from:
- MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof,
- MrgE specific antibody raised against an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof,
- a siRNA molecule that is specific to a transcript encoding an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof, is administered to the patient in an amount sufficient to modulate MrgE activity in fat tissue.
- Fig. 1 shows a multiplex quantitative RT-PCR experiment.
- RNA was isolated from various tissues and RT-PCR was performed with primers specific for Tata box binding protein (TBP) and MrgE. The signals were quantified and the MrgE signal was normalized to the TBP signal.
- TBP box binding protein
- Fig. 2 shows a multiplex quantitative RT-PCR experiment.
- RNA was isolated from 3T3 L1 cells at different days during the differentiation to adipocytes and RT-PCR was performed with two sets of primers specific for Tata box binding protein (TBP) and MrgE or for TBP and PPAR ⁇ . The signals were quantitated and the MrgE and PPAR ⁇ signals, respectively were normalized to the TBP signals.
- TBP Tata box binding protein
- Fig. 3 shows the physiological regulation of an MrgE receptor polynucleotide in mesenteric adipose tissue for rats exposed to different feeding regimes.
- One group of rats was given chow ad libitum (ad lib chow)
- one group of rats was given high energy chow mixed with chocolate spread (Nutella + HE)
- one group was given chow ad libitum and food was withdrawed 48 hours before the termination of the experiment (chow + 48 hr fast), and one group was kept at 70% of the amount of food consumed by the ad lib chow group (70% chow).
- B Multiplex quantitative RT-PCR experiment.
- Mesenteric white adipose tissue was isolated from the rats and the expression of MrgE and TBP was determined by Multiplex quantitative RT-PCR. Error bars show Standard Error of the Mean (SEM).
- Fig. 4 shows a Phobius (KaII et al. 2004) prediction of transmembrane probability of the rat Mrg E amino acid sequence.
- Phobius predicts the following regions: Extracellular: 1-19, transmembrane: 20-44, cytoplasmic: 45-55, transmembrane: 56-77, extracellular: 78-88, transmembrane: 89-112, cytoplasmic: 113-132, transmembrane: 133-153, extracellular: 154-172, transmembrane: 173-198, cytoplasmic: 199-209, transmembrane: 210-232, extracellular: 233-243, transmembrane: 244-267, cytoplasmic: 268-309. Ligand binding domains are expected to be placed in the extracellular domains.
- Fig. 5 shows a multiplex quantitative RT-PCR experiment.
- RNA from human white adipose tissue was used for RT-PCR with primers specific for TATA box binding protein (TBP) and MrgE.
- TBP TATA box binding protein
- MrgE MrgE
- oligonucleotide is a strand of nucleotide residues which has a sufficient number of bases to be used as an oligomer, amplimer or probe in a polymerase chain reaction (PCR). Oligonucleotides are prepared from genomic or cDNA sequence and are used to amplify, reveal, or confirm the presence of a similar DNA or RNA in a particular cell or tissue. Oligonucleotides or oligomers comprise portions of a DNA sequence having at least about 10 nucleotides and as many as about 35 nucleotides, preferably about 25 nucleotides.
- Reporter molecules are radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents which associate with a particular nucleotide or amino acid sequence, thereby establishing the presence of a certain sequence, or allowing for the quantification of a certain sequence.
- Chimeric molecules may be constructed by introducing all or part of the nucleotide sequence of this invention into a vector containing additional nucleic acid sequence which might be expected to change any one or several of the following MrgE characteristics: cellular location, distribution, ligand-binding affinities, interchain affinities, degradation/turnover rate, signaling, etc.
- MrgE polypeptide refers to those forms, fragments, or domains of a MrgE polypeptide which retain the biological and/or antigenic activity of a MrgE polypeptide.
- Naturally occurring MrgE polypeptide refers to a polypeptide produced by cells which have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications of the polypeptide including but not limited to acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.
- Constant amino acid substitutions result from replacing one amino acid with another having similar structural and/or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.
- “Insertions” or “deletions” are typically in the range of about 1 to 5 amino acids. The variation allowed may be experimentally determined by producing the peptide synthetically while systematically making insertions, deletions, or substitutions of nucleotides in the sequence using recombinant DNA techniques.
- inhibitor is any substance which retards or prevents a chemical or physiological reaction or response. Common inhibitors include but are not limited to antisense molecules, antibodies, and antagonists.
- Standard expression is a quantitative or qualitative measurement for comparison.
- Animal as used herein may be defined to include human, domestic (e. g., cats, dogs, etc.), agricultural (e. g., cows, horses, sheep, etc.) or test species (e. g., mouse, rat, rabbit, etc.).
- a nucleotide sequence encoding an MrqE polypeptide having a sequence according to SEQ ID NO 2: accession number NM 001002288 or SEQ ID NO 4; accession number XM-171536: SEQ ID NOs 1 and 3 are examples of nucleotide sequences encoding MrgE.
- nucleotide sequence of SEQ ID NO 1 or 3 can be varied to a large extent, due to the alternative codon usage, while still encoding a polypeptide having an amino acid sequence as given in SEQ ID NO 2 or SEQ ID NO 4.
- a nucleotide sequence encoding MrgE may furthermore be a fragment of a sequence as given in SEQ ID NO 1 or 3, or a variant thereof with a length of at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900 bases, and even up to 925 bases.
- a nucleotide sequence encoding MrgE encodes at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150, 200, 250, 300 amino acids and even up to about 305 amino acids of the sequence identified as SEQ ID NO 2 or SEQ ID NO 4.
- a fragment of a nucleotide sequence encoding MrgE furthermore preferably comprises at least the fraction of the molecule that encodes the ligand-binding domain of the molecule, denoted as extracellular domains on figure 4.
- a variant of SEQ ID NO 1 or 3 denotes all DNA sequences encoding an
- MrgE polypeptide having an amino acid sequence as given in SEQ ID NO 2 or SEQ ID NO 4, or a fragment or variant thereof.
- a variant should furthermore be understood as a DNA sequence with at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95%, and even most preferably at least 98% identity with SEQ ID NO 1 or 3. It is furthermore preferred that the ligand-binding domain of the molecule is the most highly conserved part of the molecule, preferably at least 95%, more preferably at least 98%, and even most preferably at least 99% conserved compared with SEQ ID NO 1 or 3.
- a variant of MrqE denotes a polypeptide with an amino acid identity of at least 80%, preferably, at least 85%, more preferably at least 90%, even more preferably at least 95%, and most preferably at least 98% identity with the sequence as given in SEQ ID NO 2 or 4, or a fragment thereof. It is furthermore preferred that the ligand-binding encoding domain of the molecule is the most highly conserved part of the molecule, preferably at least 95%, more preferably at least 98%, and even most preferably at least 99% conserved compared with SEQ ID NO 2 or 4. Conservative amino acid substitutions are preferred, especially in the ligand binding domains. In one embodiment the variant has substantially the same biological function as the molecule from which it is derived.
- MrqE specific antibody denotes an antibody or a pool of antibodies (e.g. monoclonal or polyclonal antibodies) that has been raised against an MrgE polypeptide according to SEQ ID NO 2 or 4, or a fragment thereof and/or a variant thereof. Preparation of antibodies is well known in the art, see Howard and Bethell, 2000 for an example (Howard and Bethell 2000)
- a nucleotide sequence that is antisense to an MrgE sequence denotes a sequence that has the capability of base pairing specifically with an MrgE transcript encoding an MrgE polypeptide having an amino acid sequence according to SEQ ID NO 2, or 4, or a variant, or a fragment thereof.
- the antisense sequence may be in the form of a single stranded DNA, RNA, PNA, or LNA molecule.
- the antisense sequence has a length of at least about 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 300, 400, 500, 600, or 700 bases.
- siRNA Small interfering RNAs were recently discovered in plants and in animals. Since their discovery in the nematode Caenorhabditis elegans (Fire et al. 1998) these 21-23-nucleotide double-stranded RNAs bearing 3 ' overhanging ends have shown a tremendous potential for the silencing of genes in experimental as well as in therapeutical settings.
- a sample derived from fat tissue denotes a sample comprising a number of components from fat tissue, e.g. transcripts expressed in fat tissue and/or proteins expressed in fat tissue.
- the proteins may of course have been subject to post-translational modification such as signal peptide cleavage, glycosylation, acylation, etc.
- a regulator of a MrqE polypeptide denotes any compound which is known to have the ability of modulating the activity of MrgE.
- Examples of MrgE regulators comprises e.g. MrgE specific antibodies.
- telomere binding refers to the interaction between a protein or peptide and an agonist, an antibody, or an antagonist.
- the present invention thus relates to a composition for use as a medicament, said composition comprising at least one compound selected from the group consisting of:
- a polynucleotide encoding an MrgE polypeptide said polynucleotide comprising the sequence of SEQ ID NO 1 , or SEQ ID NO 3, a fragment, or variant thereof.
- a polynucleotide encoding an MrgE polypeptide wherein said polypeptide comprises the amino acid sequence according to SEQ ID NO 2, or SEQ ID NO 4, or a fragment, or variant thereof,
- MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof,
- MrgE specific antibody raised against an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof,
- siRNA molecule that is specific to a transcript encoding an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof.
- the present invention thus relates to a composition for use as a medicament, said composition comprising at least one compound selected from the group consisting of:
- nucleotide sequence that is antisense to a transcript encoding an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof
- siRNA molecule that is specific to a transcript encoding an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof.
- composition for use as a medicament comprises a polynucleotide encoding an MrgE polypeptide, said polynucleotide comprising the sequence of SEQ ID NO 1 , or SEQ ID NO 3, a fragment, or variant thereof.
- composition comprises a polynucleotide encoding an MrgE polypeptide, wherein said polypeptide comprises the amino acid sequence according to SEQ ID NO 2, or SEQ ID NO 4, or a fragment, or variant thereof.
- composition comprises a MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof
- composition comprises an MrgE specific antibody raised against an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof.
- composition comprises a nucleotide sequence that is antisense to a transcript encoding an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof
- composition comprises a siRNA molecule that is specific to a transcript encoding an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof.
- the present invention relates to use of one of the compounds according to the invention for manufacturing a pharmaceutical for modulating expression of MrgE in fat tissue for treating, alleviating, or preventing obesity, and/or diabetes, and/or cardiovascular diseases.
- the present invention relates to a method of screening an MrgE polypeptide for an interaction partner said method comprising the following steps:
- MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof with a compound or an array of test compounds; and (ii) detecting binding between MrgE and a compound capable of binding MrgE.
- said method is a method for screening fat tissue for an interaction partner of an MrgE polypeptide, said method comprising the following steps:
- the present invention relates to a method of screening for therapeutic agents useful in the treatment of obesity and/or diabetes and/or cardiovascular diseases, said method comprising the following steps: (i) determining the activity of an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment or variant thereof, in the presence and optionally also in the absence of a test compound,
- the MrgE polypeptide is expressed at the surface of a cell.
- the cell is preferably grown in vitro.
- test compounds and the MrgE polypeptide are contacted in a cell-free system.
- the polypeptide is coupled to a detectable label.
- test compound is coupled to a detectable label.
- test compound or test sample displaces a ligand which is first bound to the polypeptide.
- the polypeptide is attached to a solid support.
- the present invention relates to a composition according to the invention for the treatment of obesity and/or diabetes, and/or cardiovascular diseases.
- the present invention relates to a method of treating obesity and/or diabetes, wherein at least one compound selected from:
- MrgE specific antibody raised against an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof,
- the present invention relates to a method of treating obesity and/or diabetes, wherein at least one compound selected from:
- MrgE specific antibody raised against an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof,
- a siRNA molecule that is specific to a transcript encoding an MrgE polypeptide comprising the amino acid sequence according to SEQ ID NO 2 or SEQ ID NO 4, or a fragment, or variant thereof, is administered to the patient in an amount sufficient to modulate MrgE activity in fat tissue.
- the degree of homology can readily be calculated by known methods. Preferred methods to determine homology are designed to give the largest match between the sequences tested. Methods to determine homology are codified in publicly available computer programs such as BESTFIT, BLASTP, BLASTN, and FASTA. The BLAST programs are publicly available from NCBI and other sources in the internet.
- First-strand cDNA was prepared using 1 ⁇ g total RNA, the Superscript Il RT kit, and random hexamer primers (GIBCO BRL, Gaithersburg, Maryland, USA), according to the manufacturer's instructions.
- the cDNA was diluted 1 :6 in distilled water.
- a PCR mixture was prepared.
- the number of cycles was chosen in the range where the limiting factor for the amount of product is the amount of input template cDNA.
- the final PCR reactions were mixed with 98% formamide denaturing loading buffer and loaded in duplicate and separated on a 6% (wt/vol) polyacrylamide gel, containing 7 M urea. The gel was subsequently dried, exposed to a phosphorimager screen, and the resulting scan analyzed using Quantity One (Biorad). Finally, the MrgE expression was normalized to the TBP expression (Fig. 1) The analysis showed (Fig. 1 ) that the MRG E gene is expressed in relatively high levels in the brain and in the thymus, but that there also is a substantial expression in the epididymal white adipose tissue.
- 3T3-L1 cells (a mouse fibroblast/preadipocyte cell line) were grown to confluence and induced to differentiate as described (Student et al. 1980). Briefly, preadipocytes were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10 % calf serum and 2 days after reaching confluence (day 0), differentiation was induced by culturing the cells in DMEM with 10% fetal calf serum (FCS), 167 nM insulin (INS), 0.5 mM methylisobutylxanthine (MIX), and 0.25 ⁇ M dexamethasone (DEX) for two days, DMEM with FCS and INS for two days and DMEM with FCS until RNA was isolated.
- DMEM Dulbecco's modified Eagle's medium
- FCS fetal calf serum
- INS 167 nM insulin
- MIX 0.5 mM methylisobutylxanthine
- AGTCATGTCCACAAGTCCCC-3', product length 228 bp) were used instead of the rat-specific primers mentioned above.
- the adipocyte marker PPAR ⁇ 2 is upregulated during the adipocyte differentiation, showing that the adipocytes are indeed differentiating, and, importantly, the MrgE expression is regulated during the differentiation to adipocytes.
- the preadiocyte fibroblast cell line 3T3-L1 had the highest expression of MrgE before differentiation to adipocytes.
- the expression of MrgE was turned down to approximately half the preadipocyte level at the time when the expression of PPAR ⁇ 2 was induced.
- MrgE receptor activity can influence the differentiation process, but it is believed that stimulation or inhibition of the MrgE receptor can affect preadipocyte and/or adipocyte function as well as the differentiation process leading from preadipocytes to adipocytes.
- Nutella diet is made by mixing one third powdered chow with two thirds Nutella by weight), and eight were given chow ad libitum for 30 days and fasted the last two days of the experiment. The last day of the experiment the rats were sedated with CO 2 and decapitated. The mesenteric white adipose tissue was removed and stored in 5 volumes of RNAIater until RNA preparation
- RNA preparation, synthesis of cDNA, and multiplex PCR was performed as in Example 2 above.
- Figure 3A shows the average body weight of each group of animals in the experiment; clearly demonstrating that the Nutella fed rats had a more rapid increase in body weight than the other rats. These rats became obese and standard parameters such as white adipose tissue expression of leptin was in agreement with these data (results not shown).
- the expression of MrgE was downregulated in Nutella fed rats in the mesenteric white adipose tissue (Figure 3B), well in agreement with the downregulation seen during adipose differentiation (example 3) of 3T3-L1 cells.
- modifications of gene expression is obtained by designing antisense sequences to intron regions, promoter/enhancer elements, or even to transacting regulatory genes.
- MrgE is accomplished by subcloning the cDNAs into appropriate expression vectors and transfecting the vectors into expression hosts such as, e.g., E. coli.
- the vector is engineered such that it contains a promoter for ⁇ -galactosidase, upstream of the cloning site, followed by sequence containing the amino-terminal Methionin and the subsequent seven residues of ⁇ -galactosidase.
- an engineered bacteriophage promoter useful for artificial priming and transcription and for providing a number of unique endonuclease restriction sites for cloning.
- IPTG isopropyl-P-D-thio- galactopyranoside
- the CDNA is not in the proper reading frame, it is obtained by deletion or insertion of the appropriate number of bases using well known methods including in vitro mutagenesis, digestion with exonuclease III or mung bean nuclease, or the inclusion of an oligonucleotide linker of appropriate length.
- the MrgE cDNA is shuttled into other vectors known to be useful for expression of proteins in specific hosts.
- Oligonucleotide primers containing cloning sites as well as a segment of DNA (about 25 bases) sufficient to hybridize to stretches at both ends of the target CDNA is synthesized chemically by standard methods. These primers are then used to amplify the desired gene segment by PCR. The resulting gene segment is digested with appropriate restriction enzymes under standard conditions and isolated by gel electrophoresis. Alternatively, similar gene segments are produced by digestion of the cDNA with appropriate restriction enzymes. Using appropriate primers, segments of coding sequence from more than one gene are ligated together and cloned in appropriate vectors. It is possible to optimize expression by construction of such chimeric sequences.
- Suitable expression hosts for such chimeric molecules include, but are not limited to, mammalian cells such as Chinese Hamster Ovary (CHO) and human 293 cells., insect cells such as Sf9 cells, yeast cells such as Saccharomyces cerevisiae and bacterial cells such as E. coli.
- a useful expression vector also includes an origin of replication to allow propagation in bacteria, and a selectable marker such as the ⁇ -lactamase antibiotic resistance gene to allow plasmid selection in bacteria.
- the vector may include a second selectable marker such as the neomycin phosphotransferase gene to allow selection in transfected eukaryotic host cells.
- Vectors for use in eukaryotic expression hosts require RNA processing elements such as 3'polyadenylation sequences if such are not part of the cDNA of interest.
- the vector contains promoters or enhancers which increase gene expression.
- promoters are host specific and include MMTV, SV40, and metallothionine promoters for CHO cells ; trp, lac, tac and T7 promoters for bacterial hosts ; and alpha factor, alcohol oxidase and PGH promoters for yeast.
- Transcription enhancers such as the rous sarcoma virus enhancer, are used in mammalian host cells. Once homogeneous cultures of recombinant cells are obtained through standard culture methods, large quantities of recombinantly produced MrgE are recovered from the conditioned medium and analyzed using chromatographic methods known in the art.
- MrgE can be cloned into the expression vector pcDNA3, as exemplified herein.
- This product can be used to transform, for example, HEK293 or COS by methodology standard in the art. Specifically, for example, using Lipofectamine (Gibco BRL catolog no. 18324-020) mediated gene transfer.
- MrgE is expressed as a chimeric protein with one or more additional polypeptide domains added to facilitate protein purification.
- purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine- tryptophan modules that allow purification on immobilized metals and the domain utilized in the FLAGS extension/affinity purification system (IMMUNEX Corp. , Seattle, Washington).
- the inclusion of a cleavable linker sequence such as Factor Xa or enterokinase (Invitrogen, Groningen, The Netherlands) between the purification domain and the MrgE sequence is useful to facilitate expression and purification of MrgE.
- Purified recombinant MrgE or alternatively cells expressing MrgE are useful in screening for MrgE binding partners.
- Purified recombinant MrgE as well as an expression vector encoding MrgE may furthermore form part of a pharmaceutical formulation.
- Native or recombinant MrgE may also be purified by immunoaffmity chromatography using antibodies specific for MrgE.
- an immunoaffinity column is constructed by covalently coupling the anti-MrgE antibody to an activated chromatographic resin.
- reporter gene assays have been developed for high-throughput studies of GPCRs. These include ⁇ -galactosidase, receptor selection and amplification technology (R-SAT), ⁇ -lactamase, luciferase, Fluorescense imaging plate reader (FLIPR), and aequorin.
- R-SAT receptor selection and amplification technology
- FLIPR Fluorescense imaging plate reader
- G ⁇ 16 or the even more promiscuous G ⁇ 16/z chimeras 16z25 and 16z44 have been identified that are able to translate GPCR activation into Ca 2+ mobilization, making it possible to use the FLIPR and aequorin methods that are highly amenable to automation and high-throughput identification and/or analysis of ligands.
- COS-7 cells are maintained in Dulbecco's modified Eagles's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100U/ml penicillin and 100 ⁇ g/ml streptomycin in a humidified atmosphere consisting of 5% CO 2 and 95% air at 37 °C.
- DMEM Dulbecco's modified Eagles's medium
- FBS fetal bovine serum
- the cells are seeded at a density of 20,000 cells per well in 96-well plates designed for FLIPR assays using Opti-MEM with 10% FBS in a volume of 100 ⁇ l/well.
- Transfection is carried out using Lipofectamine 2000® reagent.
- 0.2 ⁇ g of GPCR and G protein cDNAs are diluted with 25 ⁇ l of Opti-MEM and 0.2 ⁇ l of Lipofetamine 2000® is diluted with another 25 ⁇ l of Opti-MEM. They are added to the appropriate well after the 2 components are mixed for 20 min.
- transfection medium is removed from each well followed by the labelling of transfected cells with 100 ⁇ l of 2 ⁇ M Fluo-4 in calcium containing HBSS (Hank's balanced salt solution) with 20 mM HEPES, pH 7.5 and 2.5 mM probenecid for 1 h at 37 ° C.
- 70 ⁇ l of 3X drugs are prepared and aliquotted into the corresponding wells in the V-well drug plate. Changes in fluorescence are detected in the FLIPR96 with an excitation wavelength of 48 nm. The background fluorescence is adjusted to the range of 8000 to 12000 units by altering the laser power and exposure time for the FLIPR setup.
- 50 ⁇ l of each agonist solution is added to the corresponding wells, and the fluorescent emission (between 510 and 560 nm) is monitored for 3 min. Results are expressed as changes in fluorescent intensity units.
- chimeric GPCRs are constructed by combining the extracellular receptive sequences of a new isoform with the transmembrane and intracellular segments of a known isoform for test purposes. This concept was demonstrated by Kobilka et al. (Kobilka et al. 1988) who created a series of chimeric ⁇ 2- ⁇ 2 adrenergic receptors (AR) by inserting progressively greater amounts of ⁇ 2-AR transmembrane sequence into ⁇ 2-AR. The binding activity of known agonists changed as the molecule shifted from having more ⁇ 2 than ⁇ 2 conformation, and intermediate constructs demonstrated mixed specificity.
- GPCRs are expressed in heterologous expression systems and their biological activity assessed.
- One heterologous system introduces genes for a mammalian GPCR and a mammalian G-protein into yeast cells.
- the GPCR is shown to have appropriate ligand specificity and affinity and trigger appropriate biological activation (growth arrest and morphological changes) of the yeast cells.
- An alternate procedure for testing chimeric receptors is based on the procedure utilizing the purinergic receptor (P2u). Function is easily tested in cultured K562 human leukemia cells because these cells lack P2u receptors. K562 cells are transfected with expression vectors containing either normal or chimeric P2u and loaded with fura-a, fluorescent probe for Ca++. Activation of properly assembled and functional P2U receptors with extracellular UTP or ATP mobilizes intracellular Ca++ which reacts with fura- a and is measured spectrofluorometrically.
- P2u purinergic receptor
- chimeric genes are created by combining sequences for extracellular receptive segments of any new GPCR polypeptide with the nucleotides for the transmembrane and intracellular segments of the known P2u molecule. Bathing the transfected K562 cells in microwells containing appropriate ligands triggers binding and fluorescent activity defining effectors of the GPCR molecule.
- the P2u system is useful for defining antagonists or inhibitors which block binding and prevent such fluorescent reactions.
- MrgE can be used for screening therapeutic compounds by using MrgE or binding fragments thereof in any of a variety of drug screening techniques.
- MrgE is a G protein coupled receptor any of the methods commonly used in the art may potentially be used to identify MrgE ligands.
- the activity of a G protein coupled receptor such as MrgE can be measured using any of a variety of appropriate functional assays in which activation of the receptor results in an observable change in the level of some second messenger system, such as adenylate cyclase, guanylylcyclase, calcium mobilization, or inositol phospholipid hydrolysis.
- polypeptide or fragment employed in such a test is either free in solution, affixed to a solid support, borne on a cell surface or located intracellular ⁇ .
- One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, are used for standard binding assays. Test compounds might be compounds or a pool of compounds commonly used for screening 7TM receptors for interaction partners.
- Measured for example, is the formation of complexes between MrgE and the agent being tested.
- the present invention provides methods of screening for drug canditates. These methods, well known in the art, comprise contacting such an agent with MrgE polypeptide or a fragment thereof and assaying (i) for the presence of a complex between the agent and MrgE polypeptide or fragment, or (ii) for the presence of a complex between MrgE polypeptide or fragment and the cell. In such competitive binding assays, the MrgE polypeptide or fragment is typically labeled. After suitable incubation, free MrgE polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to MrgE or to interfere with the MrgE-agent complex.
- MrgE polypeptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface.
- the peptide test compounds are reacted with MrgE polypeptide and washed. Bound MrgE polypeptide is then detected by methods well known in the art.
- Purified MrgE are also coated directly onto plates for use in the aforementioned drug screening techniques.
- non-neutralizing antibodies are used to capture the peptide and immobilize it on the solid support.
- This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding MrgE specifically compete with a test compound for binding to MrgE polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic determinants with MrgE.
- the inventive purified MrgE is a research tool for identification, characterization and purification of interacting G or other signal transduction pathway proteins.
- Radioactive labels are incorporated into a selected MrgE domain by various methods known in the art and used in vitro to capture interacting molecules.
- a preferred method involves labelling the primary amino groups in MrgE with 125 I, Bolton-Hunter reagent. This reagent has been used to label various molecules without concomitant loss of biological activity.
- Labelled MrgE is useful as a reagent for the purification of molecules with which it interacts.
- membrane- bound MrgE is covalently coupled to a chromatography column.
- Cell-free extract derived from synovial cells or putative target cells is passed over the column, and molecules with appropriate affinity bind to MrgE.
- MrgE-complex is recovered from the column, and the MrgE-binding ligand disassociated and subjected to N-terminal protein sequencing.
- the amino acid sequence information is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.
- antibodies are raised against MrgE, specifically monoclonal antibodies. The monoclonal antibodies are screened to identify those which inhibit the binding of labeled MrgE. These monoclonal antibodies are then used therapeutically.
- LSTs Antibodies, inhibitors, or antagonists of MrgE or other treatments and compounds that are limiters of signal transduction (LSTs), provide different effects when administered therapeutically.
- LSTs are formulated in a nontoxic, inert, pharmaceutically acceptable aqueous carrier medium preferably at a pH of about 5 to 8, more preferably 6 to 8, although pH may vary according to the characteristics of the antibody, inhibitor, or antagonist being formulated and the condition to be treated.
- LSTs Characteristics of LSTs include solubility of the molecule, its half-life and anti- genicity/immunogenicity. These and other characteristics aid in defining an effective carrier. Native human proteins are preferred as LSTs, but organic or synthetic molecules resulting from drug screens are equally effective in particular situations.
- LSTs are delivered by known routes of administration including but not limited to topical creams and gels; transmucosal spray and aerosol; transdermal patch and bandage; injectable, intravenous and lavage formulations; and orally administered liquids and pills particularly formulated to resist stomach acid and enzymes.
- routes of administration including but not limited to topical creams and gels; transmucosal spray and aerosol; transdermal patch and bandage; injectable, intravenous and lavage formulations; and orally administered liquids and pills particularly formulated to resist stomach acid and enzymes.
- the particular formulation, exact dosage, and route of administration is determined by the attending physician and varies according to each specific situation. Such determinations are made by considering multiple variables such as the condition to be treated, the LST to be administered, and the pharmacokinetic profile of a particular LST.
- LST formulations might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular LST.
- Normal dosage amounts vary from 0.1 to 105 ⁇ g, up to a total dose of about 1 g, depending upon the route of administration.
- Guidance as to particular dosages and methods of delivery is provided in the literature (Katre et al. 1993; Kung and Goldstein 1987; Martin et al. 1993). Those skilled in the art employ different formulations for different LSTs.
- Animal model systems which elucidate the physiological and behavorial roles of the MrgE are produced by creating nonhuman transgenic animals in which the activity of the MrgE is either increased or decreased, or the amino acid sequence of the expressed MrgE is altered, by a variety of techniques.
- Examples of these techniques include, but are not limited to: 1) Insertion of normal or mutant versions of DNA encoding a MrgE, by microinjection, electroporation, retroviral transfection or other means well known to those skilled in the art, into appropriately fertilized embryos in order to produce a transgenic animal or 2) homologous recombination of mutant or normal, human or animal versions of these genes with the native gene locus in transgenic animals to alter the regulation of expression or the structure of these MrgE sequences.
- the technique of homologous recombination is well known in the art.
- MrgE replaces the native gene with the inserted gene and hence is useful for producing an animal that cannot express native MrgE'S but does express, for example, an inserted mutant MrgE, which has replaced the native MrgE in the animal's genome by recombination, resulting in underexpression of MrgE.
- Microinjection adds genes to the genome, but does not remove them, and the technique is useful for producing an animal which expresses its own and added MrgE, resulting in over expression of the MrgE.
- transgenic animal One means available for producing a transgenic animal, with a mouse as an example, is as follows: Female mice are mated, and the resulting fertilized eggs are dissected out of their oviducts. The eggs are stored in an appropriate medium such as cesium- chloride M2 medium. DNA or cDNA encoding MrgE is purified from a vector by methods well known to the one skilled in the art. Inducible promoters may be fused with the coding region of the DNA to provide an experimental means to regulate expression of the transgene. Alternatively or in addition, tissue specific regulatory elements may be fused with the coding region to permit tissue-specific expression of the transgene.
- microinjection needle which may be made from capillary tubing using a piper puller
- the egg to be injected is put in a depression slide.
- the needle is inserted into the pronucleus of the egg, and the DNA solution is injected.
- the injected egg is then transferred into the oviduct of a pseudo pregnant mouse which is a mouse stimulated by the appropriate hormones in order to maintain false pregnancy, where it proceeds to the uterus, implants, and develops to term.
- microinjection is not the only method for inserting DNA into the egg but is used here only for exemplary purposes.
- MrgE it can be extremely useful for the elucidation of the function to make tissue-specific knock-outs, particularly in adipose tissue. This will allow for the elucidation of the particular function of MrgE in the adipose tissue without disturbing brain-specific pathways including MrgE.
- One methodology for inducing tissue-specific knockouts of MrgE is to replace the native MrgE gene with an MrgE gene flanked by loxP sites in one mouse strain and then cross mice from this strain with mice expressing the ere recombinase under control of an adipocyte-specific promoter.
- MRG E is expressed in human adipose tissue
- RNA from human adipose tissue was purchased from Biochain Inc., (Hayward, CA). The RNA had been isolated from the following donors: Great Omentum (a, male 32 years; b, male, 24 years; c, male, 21 years; d, female, 30 years), Mesenterium (e, male, 23 years; f, male, 25 years), and Subcutis (g, male, 44 years).
- First-strand cDNA was prepared using 1 ⁇ g total RNA, the Superscript Il RT kit, and random hexamer primers (GIBCO BRL, Gaithersburg, Maryland, USA), according to the manufacturer's instructions.
- the cDNA was diluted 1 :6 in distilled water.
- a PCR mixture was prepared.
- the number of cycles was chosen in the range where the limiting factor for the amount of product is the amount of input template cDNA.
- the final PCR reactions were mixed with 98% formamide denaturing loading buffer and loaded in duplicate and separated on a 6% (wt/vol) polyacrylamide gel, containing 7 M urea. The gel was subsequently dried, exposed to a phosphorimager screen, and the resulting scan analyzed using Quantity One (Biorad). Finally, the MrgE expression was normalized to the TBP expression.
- RNA in Caenorhabditis elegans Nature 391: 806-811.
- Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the
- Galpha q/11 pathway Proc Natl Acad Sci U S A 99: 14740-14745. Howard, G. C. and D. R. Bethell. 2000. Basic Methods in Antibody Production and Characterization. CRC Press LLC, Boca Raton. Jensen, J., P. Serup, C. Karlsen, T.F. Nielsen, and O. D. Madsen. 1996. mRNA profiling of rat islet tumors reveals nkx 6.1 as a beta-cell- specific homeodomain transcription factor. J Biol Chem 271: 18749-
- siRNAs Mechanism of RNA
- Galpha(16/z) chimeras efficiently link a wide range of G protein- coupled receptors to calcium mobilization. J Biomol Screen 8: 39-49. Martin, F.J., M.C. Woodle, C. Redemann, A. Yau-Young, and R.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63844504P | 2004-12-22 | 2004-12-22 | |
DKPA200401980 | 2004-12-22 | ||
PCT/DK2005/050011 WO2006066599A2 (en) | 2004-12-22 | 2005-12-21 | Mas related g protein coupled receptors as drug targets |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1835928A2 true EP1835928A2 (de) | 2007-09-26 |
Family
ID=35841850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05821505A Withdrawn EP1835928A2 (de) | 2004-12-22 | 2005-12-21 | Mas g protein gekoppelte rezeptoren als arzneitargets |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1835928A2 (de) |
WO (1) | WO2006066599A2 (de) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4548299A (en) * | 1998-06-08 | 1999-12-30 | Trustees Of Boston University | Novel methods for identifying modulators of mitochondrial anion carrier activity |
GB9921684D0 (en) * | 1999-09-15 | 1999-11-17 | Zeneca Ltd | Assays |
EP1265925A2 (de) * | 2000-02-23 | 2002-12-18 | PHARMACIA & UPJOHN COMPANY | G protein-gekoppelte rezeptoren |
EP1278840A2 (de) * | 2000-03-27 | 2003-01-29 | PE Corporation (NY) | Isolierte menschliche g-proteingekoppelte rezeptoren aus der mas proto-onkogen subfamilie, humane gpcr kodierende nucleinsäuremoleküle und ihre verwendungen |
AU2001259508A1 (en) * | 2000-05-04 | 2001-11-12 | California Institute Of Technology | Pain signaling molecules |
WO2001094951A2 (en) * | 2000-06-08 | 2001-12-13 | Board Of Regents, The University Of Texas System | Inhibitors of c-reactive protein induced inflammation |
US20030162252A1 (en) * | 2000-06-30 | 2003-08-28 | Masanori Miwa | Novel g protein-coupled receptor protein and dna thereof |
CA2498264A1 (en) * | 2002-09-09 | 2004-05-13 | Nura, Inc. | G protein coupled receptors and uses thereof |
WO2004042402A2 (en) * | 2002-11-04 | 2004-05-21 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1) |
-
2005
- 2005-12-21 EP EP05821505A patent/EP1835928A2/de not_active Withdrawn
- 2005-12-21 WO PCT/DK2005/050011 patent/WO2006066599A2/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO2006066599A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006066599A2 (en) | 2006-06-29 |
WO2006066599A3 (en) | 2006-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Deussing et al. | The corticotropin-releasing factor family: physiology of the stress response | |
Wootten et al. | Allostery and biased agonism at class BG protein-coupled receptors | |
Sakurai et al. | Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior | |
JPWO2002044362A1 (ja) | 糖尿病治療剤スクリーニング方法 | |
US20090226403A1 (en) | Olfactory and pheromones G-protein coupled receptors | |
Huang et al. | Functions of the DRY motif and intracellular loop 2 of human melanocortin 3 receptor | |
JP2002525602A (ja) | 体重を調節する化合物を同定するための標的としてのgpr10 | |
JP2000106888A (ja) | 新規g―タンパク質結合レセプタ―(hfgan72y) | |
WO2007134613A1 (en) | Modulation of gpr120 activity in adipocytes/fat tissue | |
CA2333857A1 (en) | Growth hormone secretagogue related receptors and nucleic acids | |
Nagi et al. | Biased signaling: A viable strategy to drug ghrelin receptors for the treatment of obesity | |
JPWO2006068326A1 (ja) | 新規ポリペプチドおよびその用途 | |
Yuan et al. | Fenoprofen—An old drug rediscovered as a biased allosteric enhancer for melanocortin receptors | |
EP1572133B1 (de) | Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors | |
JP2004033211A (ja) | 神経ペプチド受容体およびその使用 | |
US20040038265A1 (en) | LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions | |
WO2005121356A1 (ja) | 新規スクリーニング方法 | |
KR100971270B1 (ko) | 이피에프 수용체 에세이, 화합물 및 치료학적 조성물 | |
Wang et al. | Molecular cloning and pharmacological characterization of giant panda (Ailuropoda melanoleuca) melanocortin-4 receptor | |
JP2009538623A (ja) | 視床下部プロオピオメラノコルチン(pomc)由来生物活性ペプチドに関連する障害の処置において有用な、視床下部プロオピオメラノコルチン(pomc)由来生物活性ペプチドの分泌の調節因子を同定するための方法における、gpr101受容体の使用 | |
WO2006066599A2 (en) | Mas related g protein coupled receptors as drug targets | |
JP2003527302A (ja) | 新規な神経ペプチドレセプターhfgan72のリガンドおよびそのアゴニストまたはアンタゴニストを用いる治療方法 | |
US20030171545A1 (en) | Novel Protein | |
US20030113814A1 (en) | Identification of modulators of gpr55 activity | |
JPH1118782A (ja) | 新規なヒト・ニューロテンシン・レセプター2型およびそのスプライス変種 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070529 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
17Q | First examination report despatched |
Effective date: 20071017 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20080201 |